Related Experiment Videos
[Development of the new tumor markers]
1Wako Pure Chemical Industries, Ltd. Genome Research Laboratories, Amagasaki 661-0963.
Rinsho Byori. the Japanese Journal of Clinical Pathology
|April 21, 2005
Summary
Researchers are developing novel serum tumor markers using advanced gene expression and proteomics technologies. This study focuses on evaluating a new protein marker, ALCAN, for improved cancer diagnostics and treatment selection.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Context:
- Serum tumor markers are crucial for cancer screening, prognosis, and treatment selection.
- Advancements in gene expression analysis (DNA microarray, SAGE) identify novel cancer-related genes.
- Limitations exist in correlating mRNA levels with protein abundance and serum protein levels.
Purpose:
- To explore novel serum tumor markers for malignant tumors.
- To discuss the development and evaluation of a new protein marker, ALCAN.
- To detail the process of identifying and validating candidate proteins from transcriptome and proteome data.
Summary:
- Gene expression and quantitative proteomics technologies are advancing cancer marker discovery.
- Significant differences between mRNA and protein levels necessitate proteomic approaches.
- The study details the development of ALCAN, including cDNA cloning, recombinant protein production, antibody generation, assay development, and clinical evaluation.
Impact:
- Enables the identification of novel cancer-related genes and molecular classification of cancers.
- Highlights the importance of quantitative proteomics for accurate tumor marker development.
- Provides a framework for serological evaluation of new protein candidates as diagnostic tools.